Tesamorelin in women: what the evidence actually shows

Last updated 2026-07-24

Is tesamorelin approved for women, or just men?

Tesamorelin (brand name Egrifta, and the longer-acting Egrifta SV) is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The approval language covers adult patients generally; it is not restricted to men on the label itself. Women with HIV-associated lipodystrophy are within the approved population. The practical issue is trial composition, not label wording. The two multicenter, double-blind, placebo-controlled phase 3 trials that formed the basis of approval, later pooled and reported with safety extension data, enrolled a study population that was overwhelmingly male, which is typical of HIV lipodystrophy cohorts studied in the 2000s ^[1]. That imbalance means the confidence interval around "how well does this work in women specifically" is wider than the confidence interval for men, even though the drug is legally approved for both. So the honest answer: yes, approved for women who meet the HIV lipodystrophy indication. No, the evidence base isn't sex-balanced, and nobody should read the approval as a guarantee that female-specific outcomes were separately powered and confirmed.

What did the original tesamorelin trials actually show, and how many women were in them?

The main phase 3 program pooled two trials in HIV-infected patients with excess abdominal fat, showing tesamorelin reduced visceral adipose tissue significantly versus placebo, with an acceptable safety profile through extension follow-up ^[1]. Multiple review articles summarizing the lipodystrophy program describe the same core finding: meaningful visceral fat reduction, without matching improvement in subcutaneous fat compartments ^[2][3]. What these summaries do not do, at least not in the versions most cited, is break out a detailed sex-stratified efficacy comparison as a headline result. HIV lipodystrophy trials of that era enrolled populations reflecting the epidemiology of diagnosed HIV in the U.S. and Europe at the time, which skewed male. A 2026 meta-analysis of randomized controlled trials pooling tesamorelin's body composition, hepatic fat, and metabolic and safety outcomes in HIV-associated lipodystrophy is the most current attempt to synthesize this data across trials ^[4], and it remains focused on the HIV lipodystrophy population as a whole rather than delivering a female-only efficacy figure. If you're a woman with HIV-associated lipodystrophy asking "will this work for me specifically the way it worked in the trial averages," the honest answer is: probably similarly, based on mechanism and the trials that did include women, but the female subgroup wasn't large enough in the original program to generate its own confidence interval that regulators leaned on separately.

Does tesamorelin work differently in women's body fat distribution?

Sex differences in fat distribution are real and well described in endocrinology generally, and they matter for a drug whose entire value proposition is reducing visceral fat selectively. Tesamorelin's mechanism works through the growth hormone releasing hormone (GHRH) receptor, stimulating pulsatile GH release from the pituitary, which in turn drives lipolysis preferentially in visceral fat depots ^[5][6]. One trial specifically examined fat quality, more than fat quantity, and found tesamorelin improved fat quality (a marker linked to metabolic risk) independent of changes in fat amount ^[7]. That's a meaningful nuance: the drug isn't just shrinking a fat depot, it's changing tissue characteristics tied to insulin resistance and cardiometabolic risk. This finding came from a mixed-sex HIV cohort, and there is no dedicated female-only replication of the fat-quality result. Women naturally carry more subcutaneous and gluteofemoral fat and men carry more visceral fat on average, a pattern independent of HIV status. Because tesamorelin's approved indication and its cleanest data track a population (HIV lipodystrophy) with a distinct fat redistribution pattern driven by the disease and by older antiretroviral regimens, extrapolating the visceral-selective effect to a woman's baseline fat distribution outside that disease context is not something the trial data directly supports.

Is tesamorelin studied in postmenopausal women or for age-related fat gain?

No dedicated phase 3 trial of tesamorelin for postmenopausal fat gain or general age-related visceral adiposity exists in the cited literature. The closest adjacent research is a review on growth hormone in the aging male, which discusses GH axis decline and abdominal fat accumulation with age, but that review is framed around men, not women, and is not a tesamorelin efficacy trial ^[8]. This is a case where the absence of data has to be stated plainly rather than papered over. Age-related visceral fat gain, particularly around menopause, is a real and common concern women raise. But tesamorelin's trial evidence sits almost entirely inside the HIV-associated lipodystrophy indication. Using it off-label for menopausal midsection fat is a decision made without a matching trial in that population, hormonal context, or age range on record here. Anyone considering it for that reason should treat it as an off-label extrapolation from a different disease model, not as a therapy with its own age-related-fat evidence package.

What about tesamorelin and NAFLD or liver fat in women?

Tesamorelin has real trial data on liver fat, and this is one of the stronger secondary findings in the program. A randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat and, notably, appeared to prevent fibrosis progression in HIV patients with nonalcoholic fatty liver disease (NAFLD) over the treatment period ^[9]. Follow-up mechanistic work looked at hepatic transcriptomic signatures to understand how tesamorelin changes liver gene expression in HIV-associated NAFLD ^[10], and a related proteomic and transcriptomic analysis mapped out response pathways in the same population ^[11]. A separate trial linked visceral fat reduction directly to improved liver enzyme levels in people with HIV on tesamorelin ^[12], reinforcing that the visceral-fat effect and the liver-fat effect are mechanistically connected, not two unrelated benefits. Again, these cohorts are HIV-positive populations, mixed-sex but male-skewed, and the liver benefit is documented within that disease context. NAFLD is common outside HIV, including in women with metabolic syndrome or PCOS-related insulin resistance, but tesamorelin has not been trialed as a primary NAFLD therapy in an HIV-negative population, male or female.

How is tesamorelin dosed in women, and is the dose different from men's?

The approved dosing for Egrifta and Egrifta SV is a once-daily subcutaneous injection, and population pharmacokinetic modeling in HIV-infected patients and healthy subjects has been used to characterize exposure across the studied population, without establishing a separate FDA-approved female-specific dose ^[13]. In practice, the label dose applies regardless of sex; body weight and injection technique matter more day to day than sex-based dose splitting. A post hoc analysis looking at patients with and without dorsocervical fat pads found treatment effects on abdominal visceral fat that held up across that subgroup split, which is a useful example of how post hoc analyses in this program tend to be organized around fat distribution phenotype rather than sex ^[14]. For readers wanting the specific mg amounts, injection schedule, and how the dose is prepared, the full breakdown lives on the dedicated tesamorelin dosage page, and the mixing and reconstitution steps are covered separately in the tesamorelin reconstitution guide. A dosage calculator is also available for people working out concentration and volume per injection.

Are the side effects of tesamorelin different for women?

The safety data pooled across the phase 3 program and its extension describe the standard tesamorelin side effect list: injection site reactions, joint pain (arthralgia), swelling (edema), and effects tied to elevated IGF-1, since the drug works by raising growth hormone and downstream IGF-1 levels ^[1][6]. These effects were reported in the pooled trial population as a whole; the published safety tables from that era are not commonly broken into separate male and female adverse event rates in the summaries available here. A more recent trial in people with HIV on integrase inhibitor-based antiretroviral therapy evaluated tesamorelin's efficacy and safety in a modern treatment context, adding contemporary safety data on top of the original 2010-era program ^[15]. Fluid retention and joint symptoms are the ones patients notice most; they tend to be dose-related and often ease with time or a dose adjustment, based on the general GH-axis stimulation profile described across the tesamorelin literature ^[6][16]. A full rundown of what to expect and when to call a prescriber, including how these effects present and typical time course, is on the tesamorelin peptide side effects page. Women with a personal or strong family history of hormone-sensitive conditions, active malignancy, or uncontrolled diabetes should raise that directly with a prescriber before starting, since GH-axis stimulation is not a neutral intervention for those situations.

Does tesamorelin affect cognition or mood in women?

There is emerging trial interest here, though it's specific and shouldn't be over-read. A trial examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity, testing whether reducing visceral fat and modulating the GH/IGF-1 axis produces measurable cognitive benefit in a population known to have elevated rates of HIV-associated neurocognitive disorder ^[17]. This is a genuinely interesting research direction, but it's a single population (HIV-positive adults with abdominal obesity), it's not a general cognitive-enhancement claim, and it isn't sex-stratified in a way that supports a female-specific cognitive claim. Anyone encountering marketing that implies tesamorelin sharpens cognition broadly is extrapolating well past what this trial actually tested.

Is tesamorelin safe with hormonal birth control or HRT?

There is no trial in the cited literature that specifically tests tesamorelin's interaction with oral contraceptives, IUDs, or hormone replacement therapy. This is a genuine gap, not an oversight on our part to summarize. What's known mechanistically is that tesamorelin raises GH and IGF-1, and the phase 3 trials tracked glucose metabolism and other metabolic markers as part of the safety package, since GH elevation can affect insulin sensitivity ^[6][16]. Anyone on estrogen-containing hormonal therapy, which itself affects IGF-1 and metabolic markers, should flag that combination to the prescribing clinician so glucose and IGF-1 can be monitored appropriately. This is a monitoring conversation to have directly with a prescriber, not something the published trials have already answered.

How does tesamorelin compare to other peptides women consider for fat loss?

Tesamorelin holds a different evidentiary status than most peptides marketed for body composition. It's an FDA-approved drug with two completed phase 3 trials and over a decade of post-approval safety extension data in a defined indication ^[1][3]. Contrast that with the broader peptide landscape: a 2026 review on injectable peptide therapy for orthopaedic and sports medicine physicians and a companion review on therapeutic peptides in orthopaedics both describe a field where most compounds in circulation lack this level of regulatory scrutiny or trial maturity ^[18][19]. A 2026 review in Sports Medicine on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance draws a similar distinction between approved agents and the much larger unapproved category ^[20]. | Feature | Tesamorelin (Egrifta/Egrifta SV) | Typical unapproved research peptide |

Can a compounding pharmacy legally make tesamorelin for a woman off-label?

Tesamorelin compounding sits inside a specific federal framework, and it's worth understanding before assuming any pharmacy can just make it. Under 21 U.S.C. 353a, licensed pharmacies can compound drugs for individual patients under certain conditions, generally requiring a valid prescription and either use of an FDA-approved drug as the source or a bulk substance that appears on FDA's permitted lists ^[23]. FDA maintains separate bulk drug substance lists for 503A pharmacies (21 CFR 216.23) and 503B outsourcing facilities (21 CFR 216.24), and FDA's own guidance page on bulk drug substances used in compounding under section 503A explains how substances get nominated and evaluated for those lists ^[24][25]. The agency's current list of nominated bulk substances is a working document that changes as FDA evaluates new nominations ^[26]. The practical takeaway for a woman considering an off-label compounded version, whether for a non-HIV indication or simply outside the specific approved dosing regimen, is that legality of the compounded product depends on which list (if any) tesamorelin sits on at the time, the pharmacy's licensing status (503A vs. 503B), and whether there's a valid prescription behind it. This is a regulatory detail, not a formality, and it's worth checking directly with a provider-reviewed source rather than assuming any online seller is operating within this framework. Tesamorelin Co works with providers who route prescriptions through pharmacy partners operating inside this compounding structure, rather than compounding or manufacturing anything itself.

What should a woman ask a doctor before starting tesamorelin?

Start with the indication question directly: does she meet criteria for HIV-associated lipodystrophy with excess visceral abdominal fat, which is the actual FDA-approved use, or is this an off-label conversation about general fat reduction. The distinction changes what evidence is actually backing the decision. From there, the concrete questions worth bringing to an appointment: baseline IGF-1 and glucose levels (since tesamorelin raises both, and monitoring is part of standard use per the trial safety protocols) ^[6][16], any personal or family history of active malignancy (GH-axis stimulation is generally avoided in active cancer), current hormonal medications including birth control or HRT (given the unaddressed interaction gap noted above), and realistic expectations about what "reduces visceral fat" means versus overall weight loss, since the main trials measured visceral adipose tissue specifically, not total body weight ^[1]. A lipodystrophy diagnosis itself isn't always straightforward; a review on how to diagnose a lipodystrophy syndrome and a broader approach-to-the-patient review both describe the clinical criteria and differential diagnosis process clinicians use, since fat redistribution can have multiple causes ^[27]. Getting an accurate underlying diagnosis matters more than jumping straight to a treatment decision.

Frequently asked questions

Is Egrifta the same drug as tesamorelin, and is it approved for women?

Yes, Egrifta and Egrifta SV are the brand names for tesamorelin, FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The approval isn't restricted by sex on the label, but the main phase 3 trials enrolled predominantly male participants, so sex-specific efficacy data are limited ^[1].

Were women included in the tesamorelin phase 3 trials?

Yes, women were included, but the pooled phase 3 program that supported FDA approval reflected the broader HIV lipodystrophy population of the era, which skewed heavily male ^[1]. There is no widely cited female-only efficacy breakdown from those trials, so confidence in the results is stronger for men than for women.

Can tesamorelin help with belly fat from menopause?

There's no dedicated trial testing tesamorelin for menopausal fat gain. Its evidence base is built around HIV-associated lipodystrophy, a distinct disease process. Using it for menopausal midsection fat would be off-label and unsupported by trial data specific to that population or hormonal context.

Does tesamorelin cause different side effects in women than men?

The published pooled safety data describe injection site reactions, joint pain, and swelling as the main effects tied to GH and IGF-1 elevation, reported across the trial population as a whole rather than broken out separately by sex in the commonly cited summaries ^[1][6]. No trial in this evidence base reports a distinct female-specific side effect pattern.

Is tesamorelin safe to use with birth control or hormone replacement therapy?

No trial specifically tests this interaction. Tesamorelin raises GH and IGF-1, and estrogen-containing therapies also affect IGF-1 and metabolic markers, so this combination should be flagged to a prescriber for glucose and IGF-1 monitoring rather than assumed to be neutral.

Does tesamorelin work on liver fat in women with fatty liver disease?

Trial data show tesamorelin reduces hepatic fat and may slow fibrosis progression in HIV patients with NAFLD ^[9], with mechanistic follow-up work on hepatic gene expression changes ^[10][11]. This evidence comes from mixed-sex HIV cohorts; there's no dedicated trial in HIV-negative women with NAFLD.

Is the tesamorelin dose different for women than for men?

No FDA-approved female-specific dose exists. Population pharmacokinetic modeling characterized exposure across the studied HIV-infected and healthy population without establishing separate sex-based dosing ^[13]. Body weight and technique matter more day to day; full dosing detail is on the tesamorelin dosage page.

Can a woman get tesamorelin without having HIV?

Only off-label, since the FDA approval is specific to HIV-associated lipodystrophy. Compounded off-label use depends on pharmacy licensing (503A or 503B) and whether tesamorelin sits on FDA's applicable bulk substance list at the time ^[24][25], plus a valid prescription under 21 U.S.C. 353a ^[23].

Does tesamorelin affect mood or cognition in women?

One trial studied tesamorelin's effect on neurocognitive impairment specifically in people with HIV and abdominal obesity ^[17]. This is a narrow, disease-specific finding, not a general cognitive-enhancement claim, and it isn't reported with sex-stratified results supporting a female-specific cognition claim.

How does tesamorelin's evidence compare to other fat-loss peptides for women?

Tesamorelin has completed phase 3 trials, FDA approval, and long-term safety extension data in a defined indication ^[1]. Most other peptides marketed for fat loss lack this level of regulatory review, according to recent reviews of the injectable peptide landscape in sports medicine and orthopaedics ^[18][19][20].

What questions should a woman ask before starting tesamorelin?

Ask whether she meets the actual HIV lipodystrophy indication or if this is off-label use, request baseline IGF-1 and glucose testing, disclose any hormonal medications and cancer history, and clarify that trial endpoints measured visceral fat specifically, not total body weight ^[1][6].

Is tesamorelin linked to any cancer risk in women?

The cited trial literature doesn't report an elevated cancer signal in the studied HIV lipodystrophy population, but because tesamorelin stimulates the GH/IGF-1 axis, it's generally avoided in people with active malignancy as a precaution, consistent with how GH-axis therapies are handled across the endocrinology literature ^[6][8].

Sources

1. J Clin Endocrinol Metab, pooled phase 3 tesamorelin trials (PMID 20554713): Pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data showing tesamorelin's visceral fat reduction and safety profile in HIV patients with excess abdominal fat
2. Drugs, tesamorelin review for HIV-associated lipodystrophy (PMID 21668043): Review summarizing tesamorelin's efficacy in reducing visceral fat without matching subcutaneous fat improvement
3. BioDrugs, spotlight on tesamorelin in HIV-associated lipodystrophy (PMID 22050344): Summary of tesamorelin's approval basis and clinical positioning for HIV-associated lipodystrophy
4. Obesity Research & Clinical Practice, tesamorelin meta-analysis (PMID 41545261): 2026 meta-analysis of randomized controlled trials on tesamorelin's body composition, hepatic fat, metabolic and safety outcomes in HIV-associated lipodystrophy
5. Nature Reviews Drug Discovery, Tesamorelin (PMID 21283099): Description of tesamorelin's mechanism as a GHRH analogue stimulating pituitary GH release
6. Annals of Pharmacotherapy, tesamorelin GHRF analogue review (PMID 22298602): Mechanism of tesamorelin driving lipolysis via GH/IGF-1 axis and associated safety monitoring considerations
7. AIDS, tesamorelin fat quality trial (PMID 33756511): Trial finding tesamorelin improves fat quality independent of changes in fat quantity
8. Best Practice & Research Clinical Endocrinology & Metabolism, GH in the aging male (PMID 24054930): Review of growth hormone axis decline and abdominal fat accumulation with age, framed around men
9. The Lancet HIV, tesamorelin NAFLD randomized trial (PMID 31611038): Randomized double-blind multicenter trial showing tesamorelin reduces hepatic fat and may prevent fibrosis progression in HIV-associated NAFLD
10. JCI Insight, tesamorelin hepatic transcriptomic signatures (PMID 32701508): Study of tesamorelin's effects on hepatic gene expression signatures in HIV-associated NAFLD
11. Scientific Reports, tesamorelin response pathways proteomic/transcriptomic study (PMID 34006921): Targeted proteomic and transcriptomic analysis mapping tesamorelin response pathways in HIV-associated NAFLD
12. AIDS, visceral fat reduction and liver enzymes (PMID 28832410): Trial linking tesamorelin-induced visceral fat reduction to improved liver enzyme levels in HIV
13. Clinical Pharmacokinetics, population PK analysis of tesamorelin (PMID 25358450): Population pharmacokinetic modeling of tesamorelin exposure in HIV-infected patients and healthy subjects without separate sex-based dosing
14. Journal of Clinical and Translational Science, dorsocervical fat post hoc analysis (PMID 36845310): Post hoc analysis of phase III trial data examining tesamorelin's effect with and without dorsocervical fat
15. AIDS, tesamorelin efficacy and safety with integrase inhibitors (PMID 38905488): Trial evaluating tesamorelin's efficacy and safety in people with HIV on integrase inhibitor-based therapy
16. BETA, Tesamorelin update, San Francisco AIDS Foundation (PMID 21591600): Clinical bulletin summarizing tesamorelin's effects and monitoring considerations for GH/IGF-1 elevation
17. Journal of Infectious Diseases, tesamorelin and neurocognitive impairment (PMID 39813152): Trial examining tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity
18. American Journal of Sports Medicine, injectable peptide therapy primer (PMID 41476424): 2026 review describing the regulatory and evidence landscape for injectable peptide therapies in sports medicine
19. JAAOS Global Research & Reviews, therapeutic peptides in orthopaedics (PMID 41490200): 2026 review of therapeutic peptides in orthopaedics covering applications and regulatory challenges
20. Sports Medicine, approved and unapproved peptide therapies (PMID 41966639): 2026 review distinguishing approved from unapproved peptide therapies for musculoskeletal injuries and athletic performance
21. eCFR, 21 CFR 216.23, 503A Bulk Drug Substances List: Federal regulation establishing the bulk drug substances list permitted for 503A pharmacy compounding
22. eCFR, 21 CFR 216.24, 503B Bulk Drug Substances List: Federal regulation establishing the bulk drug substances list permitted for 503B outsourcing facility compounding
23. Cornell Law/Cornell LII, 21 U.S.C. 353a, pharmacy compounding: Federal statute governing conditions under which licensed pharmacies may compound drugs for individual patients
24. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA guidance explaining how bulk substances are nominated and evaluated for the 503A compounding list
25. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): FDA's current working list of nominated bulk drug substances under evaluation for compounding use
26. Annales d'Endocrinologie, diagnosing a lipodystrophy syndrome (PMID 22748602): Clinical review describing diagnostic criteria and differential diagnosis process for lipodystrophy syndromes
27. Journal of Clinical Endocrinology and Metabolism, approach to the patient with lipodystrophy (PMID 35137140): Clinical approach guidance for diagnosing and managing patients presenting with lipodystrophy